Psoriasis patients treated with interleukin-17A (IL-17A) inhibitor secukinumab demonstrated statistically significant skin clearance, according to 2 pivotal phase 3 studies published in The New England Journal of Medicine. Read more
In response to rising compounding drug costs, pharmacy benefit managers, such as Express Scripts, have made moves to restrict their coverage for active ingredients used by compounding pharmacies. Read more
#icymi
Editorial Questions? Contact the Editorial Team. Click Here.
Sales, Reprints, Classified questions? Contact the Sales Team. Click Here.
